טוען...
Inhibitor of Apoptosis (IAP) proteins as drug targets for the treatment of cancer
Three companies, Genentech, Aegera Therapeutics/Human Genome Sciences, and Novartis, have commenced phase 1 clinical trials of inhibitor of apoptosis (IAP) antagonist ‘Smac mimetic’ compounds for the treatment of cancer. These trials represent the culmination of a line of research that commenced wit...
שמור ב:
| מחבר ראשי: | |
|---|---|
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Biology Reports Ltd
2009
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2948278/ https://ncbi.nlm.nih.gov/pubmed/20948609 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3410/B1-79 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|